Biosimilars: complements and comments on the recent statement of the SFR and CRI. Comment on: "Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)." Schaeverbeke et al. Joint Bone Spine 2018;95:399-402.

Cohen, Jean-David; Tropé, Sonia; Munos, Audrey; Bocquet, François

Cohen, Jean-David; Tropé, Sonia; Munos, Audrey; Bocquet, François.

Afiliação

Cohen JD; Rheumatology department, Lapeyronie hospital, Montpellier university hospital center, 34295 Montpellier Cedex 5, France. Electronic address: jd-cohen@chu-montpellier.fr.
Tropé S; French national patient organization against rheumatoid arthritis (ANDAR), 75014 Paris, France.
Munos A; BioCube institute, groupe IMT, 37000 Tours, France.
Bocquet F; Law and health economics department, faculty of pharmacy, Paris Descartes university, Sorbonne Paris Cité, 4, avenue de l'Observatoire, 75006 Paris, France; Health law institute (Inserm UMR S1145), Paris Descartes university, Sorbonne Paris Cité, 45, rue des Saints-Pères, 75006 Paris, France; Pharma

Joint Bone Spine ; 86(2): 287-288, 2019 03.

Article em En | MEDLINE | ID: mdl-30394338

Assuntos

Antirreumáticos; Medicamentos Biossimilares; Doenças Reumáticas; Reumatologia; Humanos

Palavras-chave

Biosimilars; Extrapolation; Interchanggeability; Nocebo; Rheumatology; Shared decision making

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Reumatologia / Doenças Reumáticas / Antirreumáticos / Medicamentos Biossimilares Limite: Humans Idioma: En Revista: Joint Bone Spine Assunto da revista: REUMATOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google